McKesson Corporation found using ticker (MCK) have now 15 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 245 and 190 with the average target price sitting at 218.4. Given that the stocks previous close was at 189.16 this is indicating there is a potential upside of 15.5%. The 50 day MA is 185.79 and the 200 day MA is 174.8. The market cap for the company is $30,339m. Company Website: http://www.mckesson.com
McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions, International, and Medical-Surgical Solutions. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and solutions for life sciences companies, including offering multiple distribution channels and clinical trial access to specific patient populations through its network of oncology physicians. The segment also sells financial, operational and clinical solutions to pharmacies; and offers consulting, outsourcing, and other services. The Prescription Technology Solutions segment operates in the healthcare delivery system to connect pharmacies, providers, payers, and biopharma for next-generation patient access and adherence solutions. The International segment provides drug distribution services, specialty pharmacy, and retail and infusion care services. The Medical-Surgical Solutions segment distributes medical-surgical supplies and provides logistics and other services to healthcare providers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.